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Ovarian cancer is the most common cause of death 
from cancers of the female genital tract [1–4]. The high 
mortality rate results in part from the frequent diagno-
sis of ovarian cancer at advanced stages. Epithelial 
tumors of ovary comprise 58% of all ovarian neoplasms 
and more than 90% of malignant tumors of ovary [5]. 
EOC arises from ovarian surface epithelium (OSE) that 
has “uncommitted” phenotype and retains the capacity 
to differentiate into different types of cells in response 
to environmental signals [6]. During ovarian carcino-
genesis, the epithelium of ovary could differentiate into 
fallopian tube epithelium (papillary serous tumors), 
endomethrial epithelium (endomethrioid tumors), 
colonic or endocervical epithelium (mucinous tumors) 
and component of endometriosis (clear cell tumors). 
The histological analysis of EOC indicate that papillary 
serous tumors represent 50–60% of all ovarian can-
cers, and the remaining tumors exhibit endometrioid 
(25%), mucinous (4%) and clear cell (4%) histology 
[7]. It is obvious that the observed tumor heterogeneity 
has a molecular basis, and the identification of molecu-
lar markers specific for different histological types of 
epithelial ovarian cancer can lead to the development 
of more effective treatment approaches.
Recently, studies from a collaborative consortium 
have led to the identification of sodium-dependent 
phosphate transporter NaPi2b as ovarian cancer an-
tigen, termed MX35 [8]. The identity of MX35 antigen 
was confirmed by screening of ovarian cancer cell line 
OVCAR3 cDNA expression library with monoclonal 
antibody MX35 and by affinity purification of MX35 
antigen followed by mass spectrometry. MX35 antigen 
was originally identified with the use of monoclonal 
antibody MX35, obtained from mice immunized with 
fresh ovarian carcinoma cells and selected by exten-
sive analysis of normal and malignant tissues and cell 
lines. Biochemical and immunohistochemical studies 
revealed that MX35 MAb recognizes a cell surface gly-
coprotein with molecular wight of about 95 kDa, which 
is overexpressed in 90% ovarian cancer specimens but 
shows restricted expression in normal tissues. Clini-
cal studies with Fab fragments of radiolabeled MX35 
antibody suggest a therapeutic potential in patients 
with ovarian cancer [9, 10].
The human sodium-dependent phosphate trans-
porter NaPi2b is encoded by SLC34A2 gene, and 
belongs to the type II family of sodium-dependent 
phosphate transporters (SLC34 family). It is involved 
in maintaining the homeostasis of inorganic phosphate 
in human body by regulating intestinal Pi absorption 
[11]. In normal tissues, the expression of NaPi2b at 
the protein level is restricted to small intestine [12], 
lung [13], liver [14], mammary and salivary glands 
[15, 16]. The overexpression of NaPi2b transporter 
was revealed in epithelial ovarian carcinomas by SAGE 
analysis and real-time RT-PCR [17]. However, there are 
THE STUDY OF PHOSPHATE TRANSPORTER NAPI2B EXPRESSION 
IN DIFFERENT HISTOLOGICAL TYPES OF EPITHELIAL 
OVARIAN CANCER
V. Gryshkova1, I. Goncharuk2, V. Gurtovyy3, Yu. Khozhayenko3, S. Nespryadko2, L. Vorobjova2, 
V. Usenko3, I. Gout1, 4, V. Filonenko1, *, R. Kiyamova1
1Department of Cell Signaling, Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, 03680, Ukraine
2National Cancer Institute, Kyiv, 03022, Ukraine
3Research and Production Center “Medical technologies”, Dnipropetrovsk 49000, Ukraine
4Department of Structural and Molecular Biology, University College London, London WC1E6BT, United Kingdom
The identification of markers that are specifically expressed by different histological types of epithelial ovarian cancer (EOC) may 
lead to the development of novel and more specific diagnostic and therapeutic strategies. Sodium-dependent phosphate transporter 
NaPi2b (or MX35 ovarian cancer antigen) is a novel perspective marker of EOC. To date, the studies on NaPi2b/MX35 expression 
in different histological types of EOC are limited. Aim: To examine NaPi2b/MX35 expression in different histological types of 
epithelial ovarian tumors. Methods: Here, we describe the analysis of NaPi2b expression in serous (n = 17), endometrioid (n = 8), 
and mucinous ovarian tumors (n = 3) by Western-blotting (WB), immunohistochemistry and RT-PCR. Results: The results of 
immunohistochemical and WB analysis showed that benign and well-differentiated malignant papillary serous tumors as well as 
well-differentiated malignant endometriod tumors overexpress NaPi2b protein. However, no overexpression of NaPi2b was detected 
in benign and malignant mucinous tumors as well as in poorly differentiated endometriod tumors. Notably, the expression NaPi2b 
mRNA was detected in all investigated histological types of EOC. Conclusion: We have shown the differential expression profile of 
NaPi2b phosphate transporter at protein level in various histological types of epithelial ovarian cancer. This finding might facilitate 
the development of more effective approaches for diagnosis and treatment of this disease.
Key Words: epithelial ovarian cancer, tumor markers, phosphate transporter NaPi2b.
Received: January 8, 2009. 
*Correspondence: Fax: +38 (044) 522-61-00 
 E-mail: filonenko@imbg.org.ua 
Abbreviations used: EOC — epithelial ovarian cancer; IH — 
 immunohistochemistry; OSE – ovarian surface epithelium; 
SLC34A2 — solute carrier family 34 (sodium phosphate), mem-
ber 2; WB — Western-blotting.
Exp Oncol 2009
31, 1, 37–42
38 Experimental Oncology 31, 37–42, 2009 (March)
almost no data concerning the expression of NaPi2b/
MX35 protein by different histological types of EOC. 
The investigation of NaPi2b expression by different 
histological types of EOC might provide the insight on 
its prognostic value and the potential for developing 
immunotherapeutic approaches in ovarian cancer.
In this study, we compared the expression of 
NaPi2b protein between normal ovarian tissues and 
different histological types of EOC, such as serous, 
endometroid and mucinous ovarian tumors.
MATERIALS AND METHODS
Tissue samples. Tumor samples were obtained 
from ovarian cancer patients (n = 28) admitted for 
tumor resection at the National Cancer Institute 
(Kyiv, Ukraine). The types of EOC were confirmed by 
histopathological examination at the Department of 
Patholo gy, National Cancer Institute (Kyiv, Ukraine). 
Normal ovarian tissue samples (n = 10), obtained du-
ring surgical treatment of the patients with endome-
trial cancer (mean age 46 years, range 19–69 years), 
were used as the control. The mean age of patients 
with ovarian cancer 47 years (range 22–69 years). 
The study was approved by the Ethics Committee of 
the Institute of Molecular Biology and Genetics, and 
consent forms were obtained from all patients.
Western-blot analysis. We have analyzed NaPi2b 
expression in 28 ovarian cancer samples and 10 nor-
mal ovarian tissue samples. Tissues samples were 
homogenized in RIPA buffer (20 mM TrisHCl, pH 7.5, 
0.150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS) 
supplemented with PMSF (Sigma, Steinheim, Germa-
ny), and Protease Inhibitor Cocktail (Sigma, Steinheim, 
Germany) and then centrifugated at 4 °C for 30 min. 
Soluble fractions of lysates (50 μg per sample) were 
separated by 8% SDS-PAGE at non-reducing condi-
tions. Separated proteins were transferred to a PVDF 
membrane for 2 h at 80 V (Perkin Elmer, Boston, MA) 
using a wet transfer cell (Pharmacia Biotech). After the 
transfer, the membrane was blocked in PBST buffer 
(1 x PBS with 0.05 % Tween), containing 3% BSA and 
then incubated with anti-NaPi2b (0.5 mg/ml) mAb [18] 
at 4 °C overnight. After extensive washing in PBST buf-
fer, the membrane was incubated with anti-mouse IgG 
secondary antibody (1 : 5000) for 1 h (Promega, Madi-
son, WI). The immune complexes were detected by 
ECL system (Amersham, Uppsala, Sweden). GAPDH 
was used as a loading control.
Immunohistochemistry. Immunohistochemical 
analysis of ovarian cancer samples with anti-NaPi2b 
MAbs was performed according to a standard proto-
col. Briefly, representative sections of ovarian tumors 
were prepared from paraffin blocks. Endogenous per-
oxidase was quenched with H2O2 (3%) in 0.01% PBS. 
After blocking of non-specific binding with avidin-biotin 
blocking solution (Vector Laboratories, Burlingame, 
CA, USA), tissue sections were incubated overnight at 
4 °C with anti-NaPi2b mAb (10 µg/ml). Then, sections 
were incubated with biotinylated secondary antibo-
dies for 2 h at room temperature at 1 : 400 dilution 
(goat anti-mouse biotinylated IgG, Sigma, Steinheim, 
Germany), followed by incubation with avidin-biotin-
peroxidase complex (Vector Laboratories, Burlin-
game, CA, USA) for 30 min at RT and developed with 
diaminobenzidine solution. Haematoxylin was used for 
counterstaining. Standard microscopy was performed 
using a Zeiss Universal microscope (Zeiss, Jena, 
Germany), and images were captured using digital 
Axiocam software.
Total RNA isolation and RT-PCR analysis. Total 
RNA was isolated by acid guanidinum-thiocyanate-
phenol-chloroform extraction procedure [19]. Briefly, 
1 ml of denaturation solution (4 M guanidinium thiocya-
nate, 25 mM sodium citrate, pH 7.0, 5% sarcosyl, 0.1 M 
2-mercaptoethanol) was added to 100 mg of homoge-
nized tissues. Sequentially, 0.1 ml of 2 M sodium acetate, 
pH 4, 1 ml of phenol (water saturated), and 0.2 ml of 
chloroform-isoamyl alcohol mixture (49 : 1) were added 
to the homogenate. After centrifugation at 10 000 g for 
20 min at 4 °C, total RNA was precipitated from aqueous 
phase with the same volume of isopropanol at –20 °C for 
1 h. The pellet was resuspended in 75% ethanol, air dried 
and dissolved in 50 μl nuclease-free water.
Total RNA (5 μg) was converted to cDNA with M-
MuLV Reverse Transcriptase (Fermentas) at 37 °C 
for 60 min using oligo dT primers. Produced cDNA 
(100 ng) were amplified using following primers — 
forward GTCATCACTAAGCCCTTCACA and reverse 
CAGGCAACCACAGAGGAC — for 30 cycles in 50 μl total 
volume of PCR buffer 5 x PCR (Fermentas) containing 
10 mM dNTP, one unit Taq polymerase, 20 pmol of each 
primer. The amplification was performed in DNA Thermal 
cycler (Perkin Elmer) under following conditions: 94 °C for 
60 s, 60 °C for 30 s and 72 °C for 60 s. Amplified products 
were separated on a 1% agarose gel and visualised.
RESULTS
In this study, we have examined NaPi2b expression 
in ovarian tumors of serous, endometroid and muci-
nous histology. In a panel of 28 ovarian tumors, there 
were 17 serous tumors (3-cystadenomas, 1 papillary 
cystadenoma and 13 papillary carcinomas); 8 endo-
metrioid tumors (1 cystadenoma, 4 well-differntiated 
and 3 poor-differentiated carcinomas); and 3 mu-
cinous tumors (1 cystadenoma, and 2 carcinomas) 
(Table). The techniques of Western blot, immunohis-
tochemistry and RT-PCR were employed to examine 
the expression profile of NaPi2b in these tumors and 
to compare them with normal ovarian tissues.
Table. The characterization of analyzed ovarian cancer samples
Histological type of 
EOC
Number of malignant samples 
(including type of differentiation)
Number of 
benign samples 
Serous Papillary 13, w/d 1
Non-papillary – 3
Endometrioid 4, w/d
3, p/d 
1
Mucinous 2, n/a 1
Notes: w/d – well-differentiated; p/d – poor-differentiated; n/a – not 
available.
Immunoblot analysis of NaPi2b expression in ovarian 
samples was performed at non-reduced conditions us-
ing monoclonal antibody raised against the extracellular 
Experimental Oncology 31, 37–42, 2009 (March) 39
loop of human NaPi2b (188–360aa). The specifity of an-
ti-NaPi2b MAb was tested with the use of recombinant 
NaPi2b expressed in bacteria as GST fussion protein 
(Fig. 1, a). Furhtermore, using WB we have confirmed 
the expression of endogenous NaPi2b protein in ovarian 
cancer cell line (OVCAR3), kidney carcinoma cell line 
(SKRC18) that are MX35 positive cell lines, and HEK293 
stably expressing NaPi2b protein (Fig. 1, b).
It has been previously demonstrated that NaPi2b 
protein is recognized on WB as a panel of immunoreac-
tive bands with different molecular weights, reflecting 
the state of the protein glycosylation [12–16, 20–22]. 
The results presented on Fig. 1, c show that NaPi2b is 
recognized in ovarian tumor tissue lysates as a band 
with molecular weight of 100 kDa. Notably, only some 
ovarian tumors overexpress NaPi2b.
Further analysis has indicated that the expression 
of NaPi2b is detected in all (13/13) investigated sam-
ples of papillary serous tumors. In the case of benign 
serous tumors, NaPi2b expression was detected only 
in papillary cystadenoma (1/1), whereas serous cys-
tadenomas with non-papillar structure did not express 
NaPi2b (0/3) (see Fig. 1, c).
In endometrioid tumors NaPi2b expression was 
found in some of tested tumors. Interestingly, well-
differentiated endometrioid carcinomas (4/4) were 
characterized by overexpression of NaPi2b, while 
poor-differentiated endometrioid carcinomas (0/3) and 
endometrioid cystadenoma (0/1) did not express de-
tectable level of Napi2b (see Fig. 1, c). The expression 
of NaPi2b protein in WB was not detected in mucinous 
cystadenoma (0/1) and mucinous carcinomas (0/2) as 
well as in control ovarian lysates (0/10) (see Fig. 1, c).
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Fig. 1. Western-blot analysis of NaPi2b protein with the use of anti-
NaPi2b MAb generated against extracellular loop (ECL) of NaPi2b. 
a, Expression of GST/NaPi2b-ECL in bacteria was induced by 1 mM 
IPTG. Total lysates were resolved by SDS-PAGE and probed with 
anti-NaPi2b MAb. b, Endogenous expression of NaPi2b protein in 
OVCAR-3, SKRC-18 cell lines and HEK293 cells stably expressing 
NaPi2b. c, Expression of NaPi2b in different types of ovarian cancer 
and normal ovary (upper part), lane 1–8 — papillary serous carci-
noma, lane 9 — papillary serous cystadenoma, lane 10 — serous 
cystadenoma, lane 11 — endometrioid cystadenoma, lane 12 — 
poor-differentiated endometrioid carcinoma, lane 13–16 — well-
differentiated endometrioid cystadenoma, lane 17 — mucinous 
cystadenoma, 18 — mucinous carcinoma, lane 19–21 — normal 
ovary. GAPDH was used as a loading control (lower part)
We performed immunohistochemical (IH) detection 
of NaPi2b in all samples of ovarian tumors mentioned 
above and normal ovarian tissues. Using IH staining the 
presence of NaPi2b was detected only on the apical 
surface of the epithelial cells that is a characteristic 
feature of NaPi2b expression.
We found that the surface epithelium of normal 
ovary as well as ovarian stroma were negative for 
NaPi2b staining (Fig. 2, a). IH analysis of serous tumors 
showed strong staining with anti-NaPi2b MAb in papil-
lary serous carcinomas (Fig. 2, b) and papillary serous 
cystadenomas (Fig. 2, c) but no staining was detected 
in serous cystadenomas with non-papillary structures 
(Fig. 2, d). Moreover, well-differentiated endometrioid 
tumors exhibited strong staining with the use of NaPi2b 
MAb (Fig. 2, e), which was absent in poor-differentiated 
and benign endometrioid tumors. All examined cases 
of benign and malignant mucinous ovarian tumors (3) 
were negative for NaPi2b (Fig. 2, f). The results pre-
sented above indicate a good correlation between the 
expression of NaPi2b protein and the histological types 
of tumors. Differential pattern of NaPi2b protein expres-
sion in various types of ovarian tumors prompted us to 
examine NaPi2b protein expression in normal tissues 
of female reproductive system, such as fallopian tubes, 
endometrium and endocervic. We observed the posi-
tive staining with NaPi2b MAb in normal fallopian tube 
epithelium (Fig. 3, a) and endometrium (Fig. 3, b) but 
not in endocervical epithelium (Fig. 3, c).
Total RNA derived from 28 ovarian cancer tissues 
and 10 normal ovarian tissues were investigated by 
RT-PCR analysis with the use of SLC34A2 specific pri-
mers (see Materials and Methods), which were designed 
for unique sequences of SLC34A2 gene. The product of 
amplification (350 bp) was analysed on an agarose gel. 
The results presented in Fig. 4, a have shown SLC34A2 
mRNA expression in all tissues analyzed.
DISCUSSION 
We have recently identified sodium-dependent 
phosphate cotransporter NaPi2b as MX35 antigen, 
which is known to be overexpressed in 90% of hu-
man ovarian cancers [8, 9]. The pattern of NaPi2b 
expression in normal tissues and ovarian cancer 
makes NaPi2b/MX35 antigen a potential target for the 
development of immunotherapeutic and diagnostic 
approaches of EOC.
NaPi2b is a transmembrane glycoprotein that pos-
sesses 8 transmembrane domains, a large extracellular 
loop (188–360aa) with several potential sites of glyco-
sylation, and the N-and C-terminal cytoplasmic tails 
facing the cytosol [8]. In addition to MX35 antibody, we 
have recently developed several monoclonal antibodies 
recognizing the extracellular loop of human NaPi2b [18]. 
To our knowledge, the expression of NaPi2b/MX35 pro-
tein in different histological types of EOC have not been 
analysed so far. The elucidation of NaPi2b expression 
profile in various types of ovarian cancer might be useful 
not only for understanding molecular mechanisms of 
carcinogenesis, but also for the verification of diagnosis, 
prognosis and treatment strategies.
In this study, we have analyzed NaPi2b expression 
at protein and mRNA levels in different types of epi-
thelial ovarian cancer and normal ovarian tissues. We 
40 Experimental Oncology 31, 37–42, 2009 (March)
have observed a good correlation of NaPi2b protein 
expression detected by WB and IH in ovarian tumor 
samples of different histological types. Our results 
showed that NaPi2b protein is overexpressed in 
papillary serous tumors and low-grade endometrioid 
tumors when compared to mucinous ovarian cancer. 
The most common histological type of EOC is papillary 
serous carcinomas, which are often associated with 
concentric rings of calcification known as psammoma 
bodies [23]. Notably, breast and papillary thyroid can-
cers, which are characterized by abberrant expression 
of NaPi2b, are also affected by calcifications [24, 25]. 
It has been demonstrated that the downregulation of 
the NaPi2b transport function results in the deposition 
a b
c d
e f
Fig. 2. Immunohistochemistry of ovarian tumors and normal ovaries samples with the use of anti-NaPi2b MAb. a, normal ovary; 
b, papillary serous carcinoma; c, papillary serous cystadenoma; d, serous cystadenoma; e, well-differentiated endometrioid car-
cinoma; f, mucinous cystadenoma
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of calcium phosphate microliths in patient’s lungs. This 
phenomenon is caused by mutations in SLC34A2 gene 
of phosphate transporter, which finally manifests by 
itself the development of pulmonary alveolar micro-
lithiasis (PAM) [26]. Based on these data we propose 
that the calcification in papillary serous ovarian cancer 
could be associated with the failure of calcium phos-
phate homeostasis due to the aberrant expression or 
mutations in NaPi2b phosphate transporter gene.
Since low tumor grade has been associated with 
good outcome and survival [27, 28], the overexpres-
sion of NaPi2b in well-differentiated papillary serous 
and endometrioid carcinomas could be a marker of 
a good prognosis. Our data correlate well with the 
results published by with Rangel et al. [17], showing 
that well differentiated epithelial ovarian tumors tend 
to express higher level of NaPi2b.
IH analysis of normal tissues of female reproductive 
system with NaPi2b MAb revealed its expression in 
fallopian tube epithelium and endometrium, but not in 
endocervical epithelium. Since ovarian surface epithe-
lium of papillary serous tumors resembles epithelium 
of fallopian tube, and endometrioid tumors — endo-
metrial epithelium, and mucinous tumors — colonic or 
endocervical epithelium [29], it is not surprisingly that 
only papillary serous and endometrioid tumor of low 
grade overexpressed NaPi2b protein. So, the overexp-
ression of NaPi2b protein in well-differentiated papil-
lary serous and endometrioid tumors is linked to dif-
ferentiation of ovarian surface epithelium into fallopian 
tubes epithelium and endometrium, respectively.
The expression of NaPi2b mRNA in different types 
of EOC showed no correlation with that of NaPi2b 
protein detected by IH and WB. We observed mRNA 
NaPi2b expression in all investigated histological types 
of EOC and did not reveal significant difference bet-
ween samples with high and low level of NaPi2b pro-
tein expression. The absence of correlation between 
NaPi2b mRNA and protein expression could indicate 
the regulation of NaPi2b expression at the level of 
translation that should be further investigated. Our 
data concerning NaPi2b mRNA expression correlate 
with the data reported by Rangel et al. [17], showing 
up-regulation of SLC34A2 expression in serous, en-
dometrioid, mucinous and clear-cell tumors of EOC 
by real-time RT-PCR analysis.
In summary, our data demonstrate that phosphate 
transporter NaPi2b is overexpressed in well-differen-
tiated papillary serous and endometrioid ovarian tu-
c
a
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Fig. 3. Immuhistochemistry of normal fallopian tubes (a), endo-
metrium (b), endocervical epithelium (c) with anti-NaPi2b mAb
a
b
1 2 3 4 5 6 7 8 M
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Fig. 4. RT-PCR analysis of ovarian tumor samples with SLC34A2 
primers (a) and primers to beta-actin (b). Lane 1 — papillary serous 
carcinoma, lane 2 — papillary serous cystadenoma, lane 3 — serous 
cystadenoma, lane 4 — endometrioid cystadeno ma, lane 5 — well-
differentiated endometrioid carcinoma, lane 6 — mucinous cysta-
denoma, lane 7 — mucinous carcinoma, lane 8 — normal ovary
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mors. Moreover, we found that differential expression 
of NaPi2b in EOC may be the consequence of changes 
in ovarian epithelium differentiation during malignant 
process. The findings of this study might facilitate the 
rational development of new diagnostic modalities and 
targeted therapies of ovarian malignancies.
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